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Abstract: Risperidone is one of the early second-generation antipsychotics that came into the 
limelight in the early 1990s. Both the oral and long-acting injectable formulations have been sub-
ject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently 
one of the most widely prescribed antipsychotic medications, used for both acute and long-term 
maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic 
symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares 
better than placebo and first-generation antipsychotics in the treatment of negative symptoms. 
Risperidone’s long acting injectable preparation has been well tolerated and is often useful in 
patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia 
comparable to first-generation antipsychotics (FGAs) but fares better than many second-gener-
ation antipsychotics with regards to metabolic side effects. In this article, we briefly review the 
recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical 
usage, and highlight the controversies and challenges associated with its use.
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Introduction
Pharmacotherapy is an essential component of the multimodal treatment approach 
required to manage complex psychiatric disorders such as schizophrenia and bipolar 
disorder. Beginning with the serendipitous discovery of chlorpromazine’s antipsy-
chotic effects, a number of agents such as perphenazine, fluphenazine, thioridazine, 
haloperidol, and thiothixene, were developed in the 1950s and 1960s. Haloperidol, 
which continues to be widely available in various formulations, was first approved by 
the United States Food and Drug Administration (FDA) in 1967. The abovementioned 
group of medications is frequently referred to as typical or first-generation antipsychot-
ics (FGAs) which act mainly by blocking the dopaminergic D2 receptors. While the 
FGAs have demonstrated efficacy in managing the positive symptoms of schizophrenia 
such as hallucinations, formal thought disorder and delusions, their use is often limited 
by their adverse effect profile, including the potential for a variety of extrapyramidal 
side effects (EPSE), such as akathisia, acute dystonia, and tardive dyskinesia (TD). 
Furthermore, their use does not address negative or cognitive symptoms, and may even 
be associated with a deleterious impact in such domains. These limitations paved the 
way for further research to identify and develop novel antipsychotic agents. Clozapine 
is widely accepted as the first atypical antipsychotic or second-generation antipsychotic 
(SGA). Though it was initially introduced in the early 1970s, it was withdrawn due to 
its association with agranulocytosis. It was reintroduced in the late 1980s with stricter 
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regulations for monitoring and was thereafter FDA-approved 
for use for treatment-resistant schizophrenia. Over the last 
two decades, the SGA group has grown exponentially, with 
the addition of risperidone, olanzapine, ziprasidone, and 
quetiapine in the 1990s, followed by aripiprazole and pali-
peridone in the next decade. In the last few years, three more 
SGAs including asenapine, iloperidone, and lurasidone have 
been added to the treatment armamentarium for pharmaco-
therapy in patients with schizophrenia. Despite a variety of 
adverse effects and limitations in efficacy, SGAs are now 
considered the first line of treatment for schizophrenia.
Another important development linked to the optimal 
management of schizophrenia has involved the development 
of various formulations of the SGAs that may be used for 
different subgroups of patients and for enhancing adherence 
to the medication regimen, an important component of the 
treatment of schizophrenia. While depot preparations and 
liquid formulations are available for enhancing adherence, 
injectable formulations and dissolving tablets may be used 
for managing aggressive patients or those who may require 
acute stabilization of symptoms.
In this review article, we briefly discuss the clinical 
usage, efficacy, tolerability, and safety, availability of vari-
ous formulations, and potential adverse effects of one of the 
earliest available SGAs, risperidone. We briefly appraise the 
role of risperidone in the treatment of positive symptoms, 
negative and cognitive symptoms of schizophrenia and as 
an adjuvant of clozapine. In addition, we discuss literature 
comparing risperidone’s efficacy with FGAs and other 
atypical antipsychotics. We also describe how risperidone 
compares to other antipsychotics in terms of traditional 
antipsychotic side effects and also metabolic side effects, 
which have emerged to be a significant adverse effect with 
second-generation antipsychotics.
Risperidone
Development of risperidone, a benzisoxazole derivative, as 
an antipsychotic emerged from research studies looking at 
the lysergic acid diethylamide (LSD) drug model of schizo-
phrenia, since such studies led scientists to target not only 
dopaminergic (DA) receptor blockade, but also the serotonin-
ergic (5-HT) antagonism.1 Risperidone was first approved by 
the FDA for management of acute schizophrenia in 1993 and 
for the long-term maintenance treatment of schizophrenia in 
2002. Risperidone is now available in a variety of formula-
tions, such as oral tablets, oral solution, orally disintegrating 
tablets, and as powder for solution for long-acting injection 
(LAI). The LAI formulation of risperidone (RLAI) and 
the oral dispersible tablet (ODT) were both approved for 
use by the FDA in 2003. The ODT formulation is reported 
to have a rapid onset of action and similar bioequivalence 
when compared to regular tablets.2 It is well tolerated and 
provides an effective alternative to parenteral haloperidol 
either alone or in combination with benzodiazepines for 
the management of severe agitation often associated with 
acute psychotic conditions.3,4 In addition to schizophrenia, 
risperidone is approved for use either as an adjunctive agent 
or as monotherapy in the acute phase of manic and mixed 
episodes of bipolar disorder type I in both adult patients and 
children aged 10 years and older. It is also approved to treat 
irritability (to include temper tantrums, deliberate self-injury, 
and aggressiveness) associated with autism in children and 
adolescents 5 years and older.
Mechanism of action
Like all the SGAs, risperidone has significant effects on 
dopamine (DA) and serotonin (5-HT) receptors (Figure 1). 
While the pharmacodynamic profile of risperidone is best 
characterized as a potent D2 antagonist with predominant 
5-HT2 antagonistic activity, it is worth noting that the D2 
antagonistic action of risperidone is 4–10 times less potent 
compared to haloperidol.5
Risperidone is also an alpha-1-adrenergic receptor 
blocker, which results in the risk of orthostatic hypotension, 
sometimes requiring a careful dose titration. It also has affin-
ity for the histaminergic H1 and alpha-2-adrenergic recep-
tors, with H1 blockage contributing to sedation, increased 
appetite, and weight gain. Risperidone is metabolized by 
cytochrome P450 (CYP) 2D6 and its major metabolite, 
9-hydroxyrisperidone, is also an effective antipsychotic.
In this article, we discuss the recent literature focusing on 
the role of risperidone in the treatment of schizophrenia.
Dosing
Any dosage regimen should be calibrated to gain maximal 
beneficial effects and minimize the adverse effects of the 
medication. Li et al reviewed the literature to find out the 
Risperidone
5HT2A
D2
α1, α2 and H1
Figure 1 Mechanism of action of risperidone. 
Abbreviations: 5HT2A, serotonin receptor 2A; D2, dopamine receptor 2; H1, 
histamine receptor 1; α1, adrenergic receptor 1; α2, adrenergic receptor 2.
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optimal dose range of risperidone for schizophrenia.6 These 
authors reviewed data from eleven trials involving 2498 
(primary outcomes) patients and noted that there is lack of 
adequate data to recommend the use of a particular dose 
range for clinical practice. However, first episode psychosis 
(FEP) patients responded well to doses of 2–4 mg/day. A dose 
range of 4–6 mg/day seemed optimal for clinical response 
and tolerability in the majority of schizophrenia patients. 
Also, patients who received less than 4 mg/day discontinued 
risperidone due to insufficient response, while patients who 
received . 10 mg/day stopped taking it due to the higher 
incidence of side-effects, especially movement disorders.
Risperidone vs placebo
In general, placebo controlled trials are believed to be 
easier to interpret than active controlled trials and negate 
the observed control group bias of atypical antipsychotic 
active control trials.7,8 In 2010, Rattehalli et al (see Table 1) 
reviewed ten randomized controlled trials (RCTs) involving 
1363 patients, looking at a comparison of risperidone with 
placebo in treatment of schizophrenia.9 Risperidone was 
found to be better than placebo in reduction of psychotic 
symptoms as measured by a . 20% reduction in brief psychi-
atric rating scale (BPRS) and positive and negative syndrome 
scale (PANSS) values. Interestingly however, there was no 
difference between risperidone and placebo in the Clinical 
Global Impression (CGI) scores. Incidence of EPSE was 
higher in the risperidone group but did not reach statistical 
significance when compared to placebo, with a relative risk 
(RR) of 1.4 and confidence interval (CI) of 0.93–2.1. These 
authors concluded that while risperidone is better than pla-
cebo in marginal improvement of symptoms and in   adherence 
to treatment, they were surprised that even after nearly two 
decades of availability of risperidone, there is a paucity 
of independent trials, especially with 7 out of 10 included 
studies in this review being industry sponsored. In their 
meta-analysis, Leucht et al reviewed 38 studies comparing 
SGAs with placebo and concluded that risperidone was more 
efficacious than placebo and had lower dropout rates.10
Risperidone vs other antipsychotics
There are ethical arguments against placebo controlled   trials 
in schizophrenia and for active controlled trials to be used 
instead. Risperidone has a favorable side-effect profile and 
has lower discontinuation rates relative to FGAs. In 2003, 
Hunter et al (see Table 1) conducted a review of studies com-
paring risperidone with FGA and noted that risperidone had 
more favorable outcomes in both short-term and long-term 
studies and a lower relapse rate at 1-year follow-up when 
compared to haloperidol.11 Risperidone was less likely to be 
associated with EPSE than haloperidol, with a RR of 0.63 and 
CI of 0.56–0.71. Therefore, add-on anti-parkinsonian medi-
cations were used less often with risperidone. These authors 
concluded that compared to a similar review in 2000,12 there 
was additional evidence to show that risperidone was not only 
marginally better in terms of clinical improvement but better 
tolerated in comparison to FGA such as haloperidol as shown 
by the lower number of risperidone subjects leaving both 
short- and long-term trials. In a randomized, open-label study 
involving 174 FEP patients treated with either haloperidol, 
risperidone, or olanzapine, Crespo-Facorro et al found that 
the discontinuation rate due to any cause for haloperidol was 
statistically significant (P = 0.014) when compared to the 
other two medications.13
Table 1 Cochrane risperidone reviews
Review Sample/studies For risperidone Against risperidone
Rattehalli et al9 
Risperidone vs placebo  
for schizophrenia
n = 1363, 10 RCTs Greater reduction in PANNS/ 
BPRS scores 
Less number of risperidone  
subjects left the trial owing  
to lack of efficacy
More EPSE but did not reach 
statistical significance 
Prolactin elevation
Hunter et al11 
Risperidone vs typical  
antipsychotic medication  
for schizophrenia
n = 2368, 9 RCTs Better outcomes in both short  
and long term trials 
Reduction in relapse rate 
Less extrapyramidal side effects
Weight gain 
Prolactin elevation and sexual 
side effects were comparable 
to haloperidol
Komossa et al14 
Risperidone vs other  
atypical antipsychotics
n = 7760, 45 RCTs Better PANNS score reduction  
than quetiapine and ziprasidone 
Better than ziprasidone in  
leaving study due to inefficacy 
Equal efficacy compared to  
aripiprazole and amisulpride
Olanzapine better on PANNS 
reduction 
Olanzapine and clozapine 
better than risperidone in 
leaving study due to inefficacy 
EPSE 
Prolactin elevation
Abbreviations: RCT, randomized controlled trial; PANNS, positive and negative syndrome scale; BPRS, brief psychiatric scale; EPSE, extra pyramidal side effects.
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Most of the literature supports the notion that there are very 
few differences in the efficacy of atypical antipsychotics, bar-
ring clozapine. More recently, Komossa et al (see Table 1) pub-
lished an interesting and extensive review of 45 RCTs involving 
7760 subjects comparing risperidone with other SGA.14 
Again, these authors caution that the current data is limited 
by a preponderance of industry sponsored trials, incomplete 
reporting of outcomes and a significant proportion (46.9%) 
of subject dropouts, thereby preventing them from drawing 
firm conclusions. Despite these limitations, they inferred that 
while looking at the PANSS scores, risperidone was slightly 
better than quetiapine and ziprasidone but marginally inferior to 
olanzapine. Furthermore, risperidone was inferior to olanzap-
ine and clozapine in terms of subjects discontinuing the study 
early due to inefficacy although it was superior to ziprasidone 
in the same measure. There was no significant difference in 
efficacy between risperidone, amisulpride, and aripiprazole. 
Risperidone was associated with higher incidence of EPSE and 
elevated prolactin levels when compared to most of the other 
SGAs. In terms of weight gain and metabolic abnormalities, 
risperidone did worse than amisulpride, aripiprazole, and 
ziprasidone but better than olanzapine and clozapine.
In their meta-analysis of around 150 studies comparing 
SGAs with FGAs, Leucht et al (see Table 2) concluded that 
amongst atypicals, risperidone, clozapine, olanzapine, and 
amisulpride were superior to first-generation antipsychotics 
in terms of treating both positive and negative symptoms. 
However, the other atypicals that were studied including 
aripiprazole, quetiapine, sertindole, ziprasidone, and zotepine 
were not more efficacious than FGA even for negative 
symptoms.15 Similarly, in another meta-analysis, Leucht et al 
reviewed 78 randomized and at least single-blinded studies 
involving 13,558 subjects, which compared several SGAs 
with each other.16 Risperidone was found to be more effica-
cious than quetiapine and ziprasidone but less efficacious than 
olanzapine and clozapine (at doses . 400 mg/day). There was 
no difference in efficacy between risperidone, aripiprazole, 
and amisulpride.
Table 2 Major recent studies involving risperidone
Study Design Results
Geddes et al63 Systematic review and  
meta-regression analysis 
52 RCTs
No major difference between typical and atypical antipsychotics 
Olanzapine though associated with weight gain, was better 
tolerated than risperidone
Davis et al64 Meta-analysis 
124 RCTs
Clozapine, olanzapine, risperidone, and amisulpride are more 
efficacious than FGAs
Leucht et al15 Meta-analysis 
150 double blind studies
Amisulpride, risperidone, clozapine, and olanzapine were more 
efficacious than first-generation antipsychotics with small-to-
medium effect sizes 
Aripiprazole, quetiapine, sertindole, ziprasidone, and 
zotepine were no different in efficacy from first-generation 
antipsychotics
Tiihonen et al65 Prospective cohort study  
using national central registers  
in Finland 
n = 2230
Clozapine, perphenazine depot, and olanzapine had the lowest 
rate of discontinuation 
Risperidone also had a significantly lower risk of all cause 
discontinuation compared with oral haloperidol 
Mortality was increased in patients not on antipsychotics
CATIE18 Double-blind RCT 
n = 1493 
 
 
 
 
n = 444
Phases 1 and 2 
Phase 1: Olanzapine had the longest time to discontinuation; 
however had worsening of weight and metabolic profile. 
Risperidone was slightly more efficacious than quetiapine and 
ziprasidone. Clozapine was superior to risperidone in terms of 
improvement in positive symptoms (Phase 2E, n = 99) 
Phase 2 T: Risperidone had advantages in those who 
discontinued medication owing to intolerability and olanzapine 
in those who discontinued owing to inadequate efficacy
CUtLASS17 12-month open-label trial 
n = 277
Compliance, quality of life, and effectiveness were similar 
between FGAs and SGAs
SOHO66 Observational, nonrandomized  
study design 
n = 6516
Olanzapine and clozapine were associated with a lower risk of 
relapse than risperidone, quetiapine, and typical antipsychotics
Abbreviations:  RCTs,  randomized  controlled  trials;  FGAs,  first-generation  antipsychotics;  CATIE,  Clinical  Antipsychotic  Trials  of  Intervention 
Effectiveness trial; CUtLASS, Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study; SGAs, second-generation antipsychotics; SOHO, 
Schizophrenia Outpatient Health Outcomes study.
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The impact of and the limitations associated with the two 
landmark studies, Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) trial and the Cost   Utility of the Latest 
Antipsychotic drugs in Schizophrenia Study (CUtLASS; see 
Table 2), have been extensively debated in the recent litera-
ture. Naber and Lambert reviewed these two studies and also 
looked at the Schizophrenia Outpatient Health Outcomes 
(SOHO) observational study and the European First-Episode 
Schizophrenia Trial (EUFEST) and concluded that even 
though SGAs failed to live up to expectations, several factors 
in comparison to FGAs such as at least equivalent efficacy, 
better quality of life-adjusted years (QALYs), and lower risk 
of tardive dyskinesia (TD) along with the beginning of avail-
ability of generic formulations of SGAs make them the favored 
first-line agents for schizophrenia.17 In terms of the CATIE 
results, probably the most alarming finding of the whole study 
was the 74% all-cause discontinuation rate. In Phase I of the 
CATIE trial involving 1460 subjects, olanzapine was found 
to be more efficacious, with a lower discontinuation rate than 
the other medication, but was also the agent most likely to be 
associated with weight gain and metabolic profile changes. 
Risperidone had the lowest discontinuation rate due to intoler-
ability but was most associated with elevated prolactin levels. 
The two components of CATIE Phase II were the 2E (efficacy, 
clozapine pathway) and 2T (tolerability, ziprasidone pathway), 
which altogether had 543 patients. Risperidone and olanzapine 
were more effective than quetiapine and ziprasidone in the 
2E. Among Phase I patients who discontinued the assigned 
agent due to tolerability, many did better on risperidone in the 
2T Phase in terms of tolerability and efficacy. Clozapine was 
clearly effective and better tolerated than all other agents in 
the 2E pathway.18
Risperidone long acting injectable 
formulation (RLAI)
LAI formulations of antipsychotics hold an important posi-
tion in the treatment of schizophrenia for patients who do 
not prefer taking medications on a daily basis or for those 
in whom there is a concern of nonadherence resulting from 
a number of issues, but especially including lack of insight. 
Adverse effects, and dosing of LAI formulations of both FGAs 
and SGAs were discussed in a recent paper by Taylor.19 Ris-
peridone was the first SGA to be formulated as a depot form 
in 2003, followed later by two other SGAs, paliperidone and 
olanzapine. RLAI differed from the oil-based preparations of 
FGA depot formulations by encapsulation of drug molecules 
into polymeric microspheres. Based on patient needs, RLAI 
is usually dosed as 25 mg, 37.5 mg, or 50 mg once every 
2 weeks and takes about 8 weeks to reach steady plasma 
levels. Hence, supplementary oral   antipsychotic treatment is 
recommended for the initial 4–6 weeks. RLAI is associated 
with a lower incidence of EPSE and risk of TD when compared 
to FGAs. The average weight gain reported with its use was 
around 3 kg over a period of 1 year. Other adverse effects 
include elevated prolactin and transient pain at the injection 
site. Two of the initial pivotal studies for RLAI involved 1194 
patients. In the first study, Kane et al performed a 12-week 
double-blind, placebo-controlled study in which 554 schizo-
phrenia patients were randomized to receive injections of 
either placebo or three different doses (25, 50, 75 mg) of RLAI 
once every 2 weeks.20 All three doses of risperidone were 
associated with statistically significant reductions in PANSS 
score (P , 0.05) when compared to placebo. RLAI was well 
tolerated with minimal weight change and the incidence of 
EPSE was reported to be 13%, 10%, 24%, 29% in placebo, 
25 mg, 50 mg, and 75 mg of RLAI, respectively. There was no 
added benefit with the higher 75 mg dosage when compared 
to 50 mg; more importantly, the higher dose was associated 
with a higher adverse effect profile. In another study involving 
640 schizophrenia patients, Chue et al used oral risperidone 
for the first 8 weeks, following which symptomatically stable 
patients were randomized to RLAI with placebo pills or pla-
cebo injections with oral risperidone.21 At the end of the study, 
both groups had a statistically significant reduction in PANSS 
(P , 0.001) and provided evidence for successful transition 
from oral to injectable form of risperidone in stable patients. 
A retrospective study involving 174 patients in Sweden found 
that switching to RLAI resulted in a significant decrease in 
duration and frequency of inpatient hospital stay.22 A similar 
reduction in utilization of inpatient resources was detected in 
a 6-month follow-up study of 79 patients and the Electronic 
Schizophrenia Treatment Adherence Registry (e-STAR) 
study of 1659 patients on RLAI who were followed up for 
24 months.23,24 In a naturalistic, multicenter European study 
involving 5134 patients who were followed up for 6 months, 
84% completed the study on RLAI.25 Only 2.3% and 2% 
discontinued RLAI due to lack of efficacy and adverse events, 
respectively. In a 6-month randomized, open-label study of 115 
patients with both schizophrenia and substance abuse, patients 
on a combination of oral and LAI risperidone showed greater 
reduction in PANSS scores, fewer positive drug screens, and 
better adherence to substance abuse treatment programs than 
patients on a combination of oral and LAI zuclopenthixol.26 
In a 2-year follow-up study of 60 patients with recent onset 
psychosis who were treated with RLAI, 72% completed the 
study while a total of 32 patients achieved remission.27 In 2009, 
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Fleischhacker conducted a review of LAI SGA preparations, 
which included an extensive review of the safety and efficacy 
of RLAI.28 The authors identified a variety of problematic 
areas with RLAI including high cost, need for initial oral 
antipsychotic supplementation, lack of guidelines regarding 
the optimal dosing, and frequency of administration.
Use of risperidone in adolescents
Schizophrenia is known to be rare in childhood with most 
reports suggesting that the onset is 50 times less common 
in children younger than 15 years compared to adults.29 
Nevertheless, the severe symptoms, which hamper academic 
and social development frequently in affected adolescents, 
require medication interventions. Clinically, because of the 
perceived tolerability (particularly less EPSE) and more 
benign side effect profiles, the use of SGAs including ris-
peridone rapidly eclipsed the typical agents in children and 
adolescents. In August 2007, risperidone became the first 
SGA to be FDA approved for use in adolescent schizophrenia 
patients and was quickly followed by aripiprazole later that 
year. Risperidone was approved mainly based on results 
from two double-blind trials, which demonstrated the safety, 
tolerability, and efficacy of risperidone in this patient popu-
lation.30 Put together, these two double-blind trials involved 
439 patients (ages 13–17 years) with an acute exacerbation 
of schizophrenia.31,32 In the first study, Haas et al compared 
two dose ranges of risperidone (1–3 and 4–6 mg/day) vs 
placebo in a 6-week duration study.31 The mean reduction 
in PANSS and CGI scores were significantly higher in both 
the risperidone groups. It was reported that EPSE, dizziness, 
and hypertonia were more common in the higher dose group. 
Compared to the baseline measure, there was . 7% weight 
gain in 15% and 16% of the lower and higher dose risperidone 
groups, respectively. The second study compared low dose 
risperidone (,1.5 mg) to a higher dose range (1.5–6 mg).32 
Clinical response was greater in the higher dose group 
(72.6% vs 49.6%; P , 0.001). Furthermore, prolactin was 
more elevated in the high dose group (97%) compared to 
the low dose group. Similarly, EPSE incidence was greater 
in the high dose group (32.8% vs 9.8%). Discontinuation 
rates owing to adverse effects were similar in both groups. 
Common adverse effects in the high-dose group included 
somnolence, weight gain, and hypertonia whereas headache, 
insomnia, agitation, and somnolence were the most com-
mon adverse effects in the low-dose group. There is general 
agreement that particularly in adolescents, as the dosage of 
risperidone approaches higher ranges, it looks more like a 
typical antipsychotic agent in terms of EPSE. In addition to 
the above two trials, since the mid-1990s, there has been at 
least one other randomized, double blinded trial, five open-
labeled studies, and a number of case reports which have 
looked at the efficacy and safety of risperidone in the child 
and adolescent population with schizophrenia.30,33–36 It has to 
be noted that patients in this age group are extremely sensitive 
to adverse effects such as akathisia, acute dystonia, EPSE, 
and metabolic complications. Hence, clinicians should be 
extra cautious and initiate treatment with lower starting doses, 
followed by gradual upward titration based on response, 
along with stringent monitoring for potential adverse events. 
Correll et al have suggested detailed strategies for recogniz-
ing and monitoring these problematic adverse effects in the 
pediatric population.37 However, even with close monitor-
ing and attention to minimizing adverse effects, medication 
compliance in the adolescent population can be problematic. 
One study of adolescents (on various medications) 14 months 
after hospitalization, found only a 38% compliance rate 
even though only 23% stopped because of side effects.38 
Findings that increased the risk for noncompliance included 
general noncompliance with the overall treatment plan and 
substance abuse. Adolescents with major mood or psychotic 
disorders including schizophrenia frequently manifest both 
of these factors.
Risperidone as an adjunct to clozapine  
in treatment-resistant schizophrenia
While clozapine is the preferred and most efficacious agent 
for the management of treatment-resistant schizophrenia, 
some patients may not respond completely to the use of 
clozapine only. In such scenarios, it is not uncommon for 
clinicians to consider augmenting clozapine with another 
antipsychotic agent. Cipriani et al conducted a literature 
review on the topic and noted that currently, the few available 
studies are limited by a small sample size, possible bias, and 
poor study designs.39 Two of the three RCTs included in this 
review used risperidone as one of the augmenting agents. 
These authors also published a review which looked at the 
addition of a second antipsychotic for patients who had a 
suboptimal response to clozapine.40 This review involved 
21 studies, of which ten used risperidone. These authors 
concluded that based on the available evidence, the benefits 
derived from adding a second antipsychotic to clozapine were 
modest to negligible.
Risperidone and cognition
In a review discussing the cognitive and psychomotor effects 
of risperidone, Houthoofd et al looked at twelve studies 
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involving patients with schizophrenia and schizoaffective 
disorder and reported that patients treated with both oral and 
LAI formulations of risperidone showed improved cognitive 
functioning in domains such as processing speed, attention, 
vigilance, verbal and visual learning, memory, reasoning, 
and problem solving.41 Risperidone did not produce any 
improvements in social cognition but was surprisingly associ-
ated with improved performance in the areas of reasoning, 
problem solving, and nonverbal working memory. These 
authors caution that this is based on limited available data and 
would need to be studied further in well-designed trials. The 
CATIE trial highlights that cognitive impairment is present in 
almost all patients and is highly correlated with impairment 
in functional outcomes.18 In contrast to previous reports of 
the modest benefit of SGAs over FGAs, data from CATIE 
indicate no differences between SGAs and perphenazine in 
providing modest cognitive enhancement.
Risperidone and negative symptoms
Leutcht et al in their meta-analysis of 38 RCTs comparing 
SGAs with placebo reported modest improvement of negative 
symptoms with antipsychotics. The effect sizes were smaller 
for negative symptoms compared to positive symptoms.10 
The same authors reviewed 150 RCTs comparing FGAs and 
SGAs, and reported an advantage for amisulpride, clozapine, 
olanzapine, and risperidone over FGAs. However, aripipra-
zole, quetiapine, sertindole, ziprasidone, and zotepine did 
not demonstrate any superiority in efficacy over FGAs in 
treating negative symptoms.15 In a different meta-analysis 
of 78 studies, Leucht et al could not identify any major dif-
ferences in SGAs in the treatment of negative symptoms 
barring a superiority of quetiapine over clozapine shown in 
two small Chinese studies.16 The addition of antidepressant 
medication to risperidone to improve negative symptoms 
has also been studied; however, these trials have yielded 
contradictory results so far.42–45
Adverse effects and important 
considerations
Risperidone is believed to work more like a FGA at doses 
of .6 mg since it blocks more than 80% of D2 receptors 
leading to the emergence of akathisia, acute dystonia, and 
EPSE.46 This is one of the key reasons that prompted a 
gradual upward titration approach in contrast to the initial 
manufacturer recommended titration of 1 mg twice daily on 
day 1, 2 mg twice daily on day 2, and 3 mg twice daily on 
day 3.47 As a class, SGAs also carry the risk of TD, although 
this risk is considered to be significantly less when compared 
to FGAs.48 In a prospective study comparing risperidone 
to haloperidol and targeting a patient population older 
than 66 years, subjects on haloperidol were more likely 
(P , 0.05) to develop TD than the risperidone group.49 In the 
SOHO study, subjects on risperidone were associated with 
a higher incidence of TD when compared to   olanzapine.50 
The association of SGAs with hyperglycemia, weight gain, 
dyslipidemia, and overall metabolic syndrome makes it 
essential that clinicians who prescribe risperidone should 
be specifically vigilant in monitoring the above mentioned 
conditions which add to the overall morbidity and mortality 
among such patients.51,52 Simon et al commented on the asso-
ciation of metabolic complications and doses of SGAs and 
reported that risperidone is associated with moderate risk of 
weight gain, hyperglycemia, type II diabetes, and low risk for 
dyslipidemia.53 However, due to a relative lack of substantial 
data, no firm conclusions can be drawn about dose-related 
metabolic complications of risperidone. In a meta-analysis, 
Smith et al noted that the relative risk of diabetes with SGAs 
when compared to FGAs was 1.32 but there is not enough 
evidence available to differentiate individual antipsychotics 
based on their risk of precipitating diabetes.54 Furthermore, 
these researchers suggested that due to insufficient data, 
aripiprazole, ziprasidone, and amisulpride were not included 
in the analysis. Madhusoodanan et al looked at the risk of 
hyperprolactinemia with psychotropics and noted that in 
comparison to other SGAs, risperidone causes more marked 
elevations in prolactin.55 A variety of reasons have been cited 
for this, including the effects of risperidone’s metabolite, 
9-hydroxy risperidone, and the higher occupancy of D2 at 
the pituitary level compared to the striatum. The incidence 
of hyperprolactinemia and its consequences, such as amen-
orrhea, galactorrhea, gynecomastia, and sexual dysfunction 
in risperidone-treated patients is 1%–10%. When compared 
to FGAs, the prolactin elevation seen with risperidone was 
found to be lower in some but higher in other studies. It 
should be noted that once elevated, the prolactin levels 
may remain high for many months in some patients.33 In an 
extensive review of tolerability of SGA in schizophrenia and 
bipolar disorder, Edwards and Smith noted that risperidone 
was the most widely prescribed SGA in the identified trials 
and it was also associated with higher risk of nausea, EPSE, 
anti-cholinergic medication use, and sexual dysfunction when 
compared to other SGAs.56 As a group, SGAs are associ-
ated with a 0.2% risk of incidence of neuroleptic malignant 
syndrome (NMS).57
SGAs are known to cause impaired glucose tolerance and 
are associated with diabetes. They have an adverse effect 
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on lipid profile especially triglycerides.58 Risperidone has 
less hyperglycemic effects relative to olanzapine; however, 
it also has adverse effects on fasting glucose and plasma 
glucose following glucose challenge compared to healthy 
volunteers.59 Olfson et al found clozapine, olanzapine, ris-
peridone, quetiapine, and ziprasidone, but not aripiprazole, 
to be associated with hyperlipidemia.60 Rummel-Kluge et al 
conducted a meta-analysis of 48 studies studying metabolic 
side effects of atypical antipsychotics, and concluded that 
olanzapine and clozapine produced more weight gain than 
other atypical antipsychotics.61 Risperidone produced more 
weight gain than amisulpride, but less than sertindole. 
  Olanzapine and quetiapine caused more increase in choles-
terol than risperidone.
Conclusion
The conceptualization of schizophrenia as a ‘tripartite con-
struct’ involving dysfunction across the domains of positive 
symptoms, negative symptoms, and interpersonal deficits, 
occurred in the 1970s.62 More than 30 years later, we are 
still far from finding specific agents that could target these 
specific symptom clusters optimally. Despite their obvious 
clinical benefits, both FGAs and SGAs have fallen short of 
expectations, whereas adverse effects and the requirement 
of intense monitoring for agranulocytosis limit the use of 
clozapine. SGAs are increasingly being recognized as a 
heterogeneous group of medications with their own advan-
tages and disadvantages and an individualized case-by-case 
pharmacologic approach is being advocated. Similar to other 
SGAs, the literature available on risperidone is dominated 
by industry-sponsored research.
Risperidone is well tolerated and has proven efficacy in 
treating the positive symptoms of schizophrenia, however, 
it is limited by modest effect sizes for treating negative 
symptoms. It has a proven role in treating not only patients 
with acute and chronic schizophrenia, but also those with 
first episode psychosis or belonging to the adolescent popu-
lation. Adverse effect profile, especially the risk of hyper-
prolactinemia and tardive dyskinesia, and metabolic profile 
must be taken into consideration whilst weighing it against 
other antipsychotics. While the generic availability of oral 
risperidone is changing the pharmacoeconomics of schizo-
phrenia treatment to some extent, adverse effects similar to 
other agents in the SGA group can limit its use. The avail-
ability of risperidone in a variety of formulations provides 
the clinician with a choice of recommending patient-specific 
SGA preparation. This is especially important in specific 
subgroup of patients, especially those where adherence to 
the treatment regimen is questionable. On the other hand, it 
may not be the most helpful agent in young females due to 
a significant risk for prolactin elevation. Even so, years of 
clinical experience, ease of generic availability, and avail-
ability in different formulations make risperidone a clinical 
and research standard for comparing the efficacy of newer 
or emerging antipsychotic therapies.
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